Supplementary Methods and Figure Legends from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Xing Huang,Qi Zhang,Yu Lou,Junli Wang,Xinyu Zhao,Lin Wang,Xiaozhen Zhang,Shanshan Li,Yulan Zhao,Qi Chen,Tingbo Liang,Xueli Bai

DOI: https://doi.org/10.1158/2326-6066.22542108

2023-01-01

Abstract:Supplementary Materials and Methods, and Supplementary Figure legends.

What problem does this paper attempt to address?

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Xiaohui Fan,Randall J. Brezski,Hui Deng,Pooja Dhupkar,Yun Q. Shi,Anneliese Gonzalez,Songlin Zhang,Michael A. Rycyzyn,William R. Strohl,Robert E. Jordan,Ningyan Zhang,Zhiqiang An

DOI: https://doi.org/10.1158/1535-7163.22501711

2023-01-01

Abstract:Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
Supplementary Figures S1-S8 from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Xing Huang,Qi Zhang,Yu Lou,Junli Wang,Xinyu Zhao,Lin Wang,Xiaozhen Zhang,Shanshan Li,Yulan Zhao,Qi Chen,Tingbo Liang,Xueli Bai

DOI: https://doi.org/10.1158/2326-6066.22542111.v1

2023-01-01

Abstract:This file contains supplemental figures S1-S8, and the detailed description is as follows: Figure S1 shows USP22 binding to HLEET motif of CD274. Figure S2 shows USP22 stabilizing CD274 in CDK4-independent manner. Figure S3 shows the non-requirement of CD274 for USP22-controlled cancer cell growth in vitro. Figure S4 shows the expression profile of USP22 in multiple cancers. Figure S5 shows the CD274-independent roles of USP22 in liver cancer growth and therapy. Figure S6 shows the expression levels of CD274 in USP22-regulated tumor immunity. Figure S7 shows the negative correlation of USP22 and immune signatures in LIHC. Figure S8 shows the schematic model.
Supplementary Methods and Figure legends from Reducing CD73 Expression by IL1β-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors

Shilpak Chatterjee,Krishnamurthy Thyagarajan,Pravin Kesarwani,Jin H. Song,Myroslawa Soloshchenko,Jianing Fu,Stefanie R. Bailey,Chenthamarkshan Vasu,Andrew S. Kraft,Chrystal M. Paulos,Xue-Zhong Yu,Shikhar Mehrotra

DOI: https://doi.org/10.1158/0008-5472.22403504

2023-01-01

Abstract:<p>The document contains supplementary methods and figure legends for supplementary figure 1, 2 and 3.</p>
Supplementary Methods and Materials, Figure Legend from ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM

Xuesong Liu,Matthew Genet,Jenna E. Haines,Elie K. Mehanna,Shanshan Wu,Hung-I Harry Chen,Yidong Chen,Abrar A. Qureshi,Jiali Han,Xiang Chen,David E. Fisher,Pier Paolo Pandolfi,Yuan Zhang

DOI: https://doi.org/10.1158/1541-7786.22514197

2023-01-01

Abstract:Supplementary Methods and Materials, Figure Legend
Supplementary Figure Legend from Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells

Helena Mistry,Grace Hsieh,Sara J. Buhrlage,Min Huang,Eunmi Park,Gregory D. Cuny,Ilene Galinsky,Richard Stone,Nathanael S. Gray,Alan D. D’Andrea,Kalindi Parmar

DOI: https://doi.org/10.1158/1535-7163.22497586.v1

2023-01-01

Abstract:PDF - 90KB, Legends for Supplemental Figures 1 through 6.
Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Tingyu Wu,Wei Chen,Yongwang Zhong,Xiaodan Hou,Shengyun Fang,Chen-Ying Liu,Guanghui Wang,Tong Yu,Yu-Yang Huang,Xuesong Ouyang,Henry Q.X. Li,Long Cui,Yili Yang

DOI: https://doi.org/10.1158/1535-7163.22507968.v1

2023-01-01

Abstract:Bortezomib and KPT330 co-treatment inhibit patients-derived xenografts in nude mice.
Supplementary Methods, Figure Legends 1-2 from Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity Against B-Cell Lymphoma

Bohua Li,Xunming Zhang,Shu Shi,Lei Zhao,Dapeng Zhang,Weizhu Qian,Lei Zheng,Jie Gao,Hao Wang,Yajun Guo

DOI: https://doi.org/10.1158/0008-5472.22382859.v1

2023-01-01

Abstract:Supplementary Methods, Figure Legends 1-2 from Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity against B-Cell Lymphoma
Supplementary Methods from Flightless-I Blocks P62-Mediated Recognition of LC3 to Impede Selective Autophagy and Promote Breast Cancer Progression

Jian-Ping He,Pei-Pei Hou,Qi-Tao Chen,Wei-Jia Wang,Xiao-Yu Sun,Peng-Bo Yang,Ying-Ping Li,Lu-Ming Yao,Xiaotong Li,Xin-Dong Jiang,Kun-Yi Chien,Zhi-Ming Zhang,Qiu-Wan Wu,Allison J. Cowin,Qiao Wu,Hang-Zi Chen

DOI: https://doi.org/10.1158/0008-5472.22425894

2023-01-01

Abstract:Supplementary materials and methods and supplementary figure legends.
Supplementary Methods, Figure Legends from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Stephen J. Blake,Kimberley Stannard,Jing Liu,Stacey Allen,Michelle C.R. Yong,Deepak Mittal,Amelia Roman Aguilera,John J. Miles,Viviana P. Lutzky,Lucas Ferrari de Andrade,Ludovic Martinet,Marco Colonna,Kazuyoshi Takeda,Florian Kühnel,Engin Gurlevik,Günter Bernhardt,Michele W.L. Teng,Mark J. Smyth

DOI: https://doi.org/10.1158/2159-8290.22530993

2023-01-01

Abstract:Supplementary Methods, Figure Legends
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Figure and Table Legends 1-4 from Combinatorial Pharmacologic Approaches Target EZH2-mediated Gene Repression in Breast Cancer Cells

Feng Sun,Eli Chan,Zhenlong Wu,Xiaojing Yang,Victor E. Marquez,Qiang Yu

DOI: https://doi.org/10.1158/1535-7163.22485608

2023-01-01

Abstract:Supplementary Figure and Table Legends 1-4 from Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
Supplementary Figures Legends from Qa-1<sup>b</sup> Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing

Xiao Zhang,Erich Sabio,Chirag Krishna,Xiaojing Ma,Jingming Wang,Hui Jiang,Jonathan J. Havel,Timothy A. Chan

DOI: https://doi.org/10.1158/1541-7786.22526916.v1

2023-01-01

Abstract:Supplemental Figure Legends 1-4
Supplementary Methods, Figure Legends from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression

Shinan Li,Rui Sun,Yongyan Chen,Wei H,Zhigang Tian

DOI: https://doi.org/10.1158/0008-5472.22407825

2023-01-01

Abstract:Supplemental Materials and Methods and Figure Legends
Supplementary Methods, Figure Legends from Targeting of Mir34a–notch1 Axis Reduced Breast Cancer Stemness and Chemoresistance

Eun Young Park,EunSun Chang,Eun Ji Lee,Hyun-Woo Lee,Hyeok-Gu Kang,Kyung-Hee Chun,Yu Mi Woo,Hyun Kyung Kong,Je Yeong Ko,Hiromu Suzuki,Erwei Song,Jong Hoon Park

DOI: https://doi.org/10.1158/0008-5472.22403286.v1

2023-01-01

Abstract:Supplementary Methods, Figure Legends
Supplementary Materials and Methods, Tables and Figure Legends from A20/TNFAIP3 Regulates the DNA Damage Response and Mediates Tumor Cell Resistance to DNA-Damaging Therapy

Chuanzhen Yang,Weicheng Zang,Zefang Tang,Yapeng Ji,Ruidan Xu,Yongfeng Yang,Aiping Luo,Bin Hu,Zemin Zhang,Zhihua Liu,Xiaofeng Zheng

DOI: https://doi.org/10.1158/0008-5472.22417212

2023-01-01

Abstract:Supplementary Materials and Methods, Tables S1-2, and Figure legends
Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Enxiu Wang,Liang-Chuan Wang,Ching-Yi Tsai,Vijay Bhoj,Zack Gershenson,Edmund K. Moon,Kheng Newick,Jing Sun,Albert Lo,Timothy Baradet,Michael D. Feldman,David M. Barrett,Ellen Puré,Steven Μ. Albelda,Michael C. Milone

DOI: https://doi.org/10.1158/2326-6066.22538600.v1

2023-01-01

Abstract:Figure legends for supplemental data.
Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Huafeng Wei,Hao Wang,Bing Lu,Bohua Li,Sheng Hou,Weizhu Qian,Kexing Fan,Jianxin Dai,Jian Zhao,Yajun Guo

DOI: https://doi.org/10.1158/0008-5472.22375065.v1

2023-01-01

Abstract:Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells
Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Xin Zheng,Xiaolei Fan,Binqing Fu,Ming–Hua Zheng,Aimei Zhang,Kai Zhong,Jun Yan,Rui Sun,Zhigang Tian,Wei H

DOI: https://doi.org/10.1158/0008-5472.22414839.v1

2023-01-01

Abstract:Supplementary Figure 1-6 legends

Supplementary Methods and Figure Legends from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figures S1-S8 from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Supplementary Methods and Figure legends from Reducing CD73 Expression by IL1β-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors

Supplementary Methods and Materials, Figure Legend from ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM

Supplementary Figure Legend from Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells

Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Supplementary Methods, Figure Legends 1-2 from Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity Against B-Cell Lymphoma

Supplementary Methods from Flightless-I Blocks P62-Mediated Recognition of LC3 to Impede Selective Autophagy and Promote Breast Cancer Progression

Supplementary Methods, Figure Legends from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure and Table Legends 1-4 from Combinatorial Pharmacologic Approaches Target EZH2-mediated Gene Repression in Breast Cancer Cells

Supplementary Figures Legends from Qa-1&lt;sup&gt;b&lt;/sup&gt; Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing

Supplementary Methods, Figure Legends from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression

Supplementary Methods, Figure Legends from Targeting of Mir34a–notch1 Axis Reduced Breast Cancer Stemness and Chemoresistance

Supplementary Materials and Methods, Tables and Figure Legends from A20/TNFAIP3 Regulates the DNA Damage Response and Mediates Tumor Cell Resistance to DNA-Damaging Therapy

Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Supplementary Figures Legends from Qa-1<sup>b</sup> Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing